A new methodology based on Nuclear Magnetic Resonance (NMR) was developed to determine plasma protein binding (PPB) of drug candidates in drug discovery programs. A strong correlation was found between the attenuation of NMR signals of diverse drugs in the presence of different plasma concentrations and their fraction bound (f b ) reported in the literature. Based on these results, a protocol for a rapid calculation of f b of small molecules was established. The advantage of using plasma instead of purified recombinant proteins and the possibility of pool analysis to increase throughput were also evaluated. This novel methodology proved to be very versatile, cost-effective, fast and suitable for automation. As a plus, it contemporarily provides a quality check and solubility of the compound.
Introduction
Plasma protein binding (PPB) role in modulating the effective drug concentration at the pharmacological target has been extensively discussed in the literature [1] [2] [3] . Knowledge of the unbound drug concentration across species (preclinical and human) in a drug discovery program supports interpretation of PK/PD relationships and extrapolation of efficacy and safety margins from preclinical species to the clinical setting.
Plasma is a complex matrix, containing diverse proteins, glucose, metabolites, clotting factors, electrolytes, hormones, etc. The major plasma proteins that drugs bind to are human serum albumin (HSA), acid alpha-1-glycoprotein (hAGP) and lipoproteins. HSA is the most abundant, with an average concentration in healthy subjects of 600 M and quite stable levels except for extreme disease states. HSA has different binding sites capable of binding endogenous compounds, in particular fatty acids, as well as xenobiotics, with a preference for acidic and neutral compounds. hAGP, whose concentration varies from 15 to 30 M, shows a preference to bind basic and neutral compounds, and its concentration and even binding capacity can significantly change in disease/inflammation states [4] .
Even though it is widely accepted that reducing the binding to these plasma proteins should lead to a higher fraction of active drug (free drug theory, FDT) [5] , it is yet crucial to understand if the fraction bound (f b ) is really predictive of drug efficacy or toxicity before investing resources in PPB optimization.
The accurate determination of f b of drug candidates is not always straightforward with the currently available methods, like ultrafiltration, ultracentrifugation and rapid equilibrium dialysis (RED) [6, 7] . Equilibrium dialysis is the most commonly used method. However, this technique is not suitable for compounds that are unstable in plasma (<3-5 h). Another critical aspect of RED as well as of ultrafiltration is the adsorption at membranes and on the surfaces of devices of some compounds that significantly impacts the measurement. Furthermore, using ultrafiltration, in some cases the free compound may be under-represented due to molecular sieving, especially when increasing the molecular size of the compound. On the other hand, ultracentrifugation requires long centrifugation times, presents a low throughput and is an expensive technique [6] .
Recognizing the utility of NMR as a very sensitive method for detecting binding, we have focused on developing an approach particularly fast and with low cost per sample, without considering the cost of the spectrometer, alternative to those currently used for determining PPB. niques with relatively high throughput and low resource usage are suitable for screening the protein binding of several compounds in a drug discovery program. Several fast, ligand-focused 1D NMR experiments exist that exploit differences in relaxation rates, diffusion rates, saturation transfers, or NOE transfers to identify protein-ligand complexes [8] . However, the fastest and simplest NMR method for evaluating protein binding is the traditional 1D 1 H line-broadening experiment, which additionally allows by a single-point measurement easily rank binding affinities [9] .
Signals of small molecules (MW < 500 Da), as normally potential drug candidates are, in 1D 1 H NMR experiments are usually very sharp due to fast tumbling in solution and a consequent slow T 2 relaxation. Binding to high MW molecules, such as plasma proteins, induces peak broadening and the corresponding decrease of the ligand's NMR signal intensity because the bound ligand experiences the shorter relaxation time of the protein. This happens if the exchange regime is fast enough in NMR time scale. The observed increase in ligand line width in such an experiment will depend on several factors that include the dissociation equilibrium constant for the protein-ligand interaction, the fraction of bound ligand, the free ligand NMR line width, and the line width for the bound state of the ligand [9] . Taking into account that plasma is a complex matrix system, we decided for an empirical approach. For twentyfive drugs (see tables I and II) we observed a strong correlation between the attenuation of NMR signals in the presence of different plasma dilutions and their f b reported in the literature. Based on these results, a protocol for a rapid and low cost calculation of f b of small molecules was established. In this manuscript, we describe this novel validated method to determine plasma protein binding (PPB) of drug candidates in drug discovery programs.
Furthermore, the advantage of using plasma instead of purified recombinant proteins, as some other methods do, and the possibility of incorporating pool analysis to increase throughput are discussed. As a plus, this method contemporarily provides a quality check and solubility of the compound.
Materials and methods

Chemicals and reagents
Acetaminophen, 1-(1-Adamantyl)ethylamine, Atenolol, Bupropion, Carbamazepine, Cefaclor, Cefsulodin, Cephalexin, Chlorpromazine, Clofibrate, Diclofenac, Diflunisal, Digitoxin, Ethinyl Estradiol, Furosemide, Haloperidol, Ibuprofen, Imipramine, Ketoconazole, Labetalol, Naproxen, Nortriptyline, Omeprazole, Phenytoin, Phenylbutazone, Procainamide, Sulfamethoxazole, Salicylic Acid, Ranitidine, Tamoxifen, Trimethoprim, Urapidil, Verapamil, Warfarin and Zidovudine were purchased from Sigma Aldrich. Dimethyl sulfoxide-d 6 (99.9% D) was obtained from Euriso-top. 3-(trimethylsilyl) propionic-2,2,3,3-d 4 acid sodium salt (TSP), sodium formate, and human alpha1-acid glycoprotein were purchased from Sigma Aldrich. Plasma matrixes were pools from four healthy subjects and was obtained from CliniSciences. Phosphate Buffer Saline with 10% D 2 O (PBS; pH 7.4) used was of analytical grade and proven pH. 
NMR spectroscopy
All NMR spectra were collected on a Bruker 600 MHz Avance spectrometer using a 5 mm BBI probe equipped with z-axis gradient and using a SampleJet sample changer and TopSpin2.1pl8 software for automated data collection. Spectra were collected at 37 • C, using a cpmg sequence with a T 2 filter of 40 ms, a sweepwidth of 7246 Hz, 32 K data points, 584 scans and a relaxation delay of 2.0 s. The residual H 2 O resonance signal was suppressed using pre-saturation. The total experiment time, including sample changing for each spectrum, was approximately 20 min. Spectra were processed with Topspin. FIDs were Fourier transformed using an exponential weighting function with a line-broadening factor of 0.5 Hz and zero filled using 65 K points. NMR spectra were phase adjusted and baseline-corrected. When possible, we focused on the aromatic resonance peaks. For the quality check, the number, multiplicity and position of the peaks in the spectrum were compared with those expected considering the chemical structure of each compound. In addition, an estimation of the solubility was obtained from integration of the aromatic signals relative to the TSP signal. Overall, peak intensity was normalized relative to the formate peak at 8.52 ppm, which was used as a shimming control. Individual peak intensities in the aromatic region for each compound were summed to obtain the free (I F ) and bound (I B ) intensities at each plasma dilution point. I B /I F values were directly obtained using Bruker Topspin 2.1 software, after base line correction by overlapping the NMR spectra obtained in the absence and in the presence of plasma. The reported value takes into consideration all the aromatic signals of each compound, and the result represents the average of three replicates ± SD. I B /I F errors thus estimated were included and propagated in the f b calculation, using the equations obtained from the calibration curves of Fig. 3 at the corresponding plasma dilutions.
Results
1D 1 H NMR line-broadening of small molecules is observed in the presence of plasma
We have investigated the effect of the presence of plasma on the NMR line width of different drugs (Fig. 1 ). In case a fast exchange between free and bound states exists, interaction with plasmatic proteins yields broader NMR signals. This effect is due to a reduced average transversal relaxation time (T 2 ) of the interacting molecule, in equilibrium between the free state (long T 2 ) and the bound state (short T 2 ). Signal broadening brings with the consequent reduction of the intensity. As comparing signal intensities is more easy and straightforward than comparing line widths, we decided to evaluate the plasma protein interaction by examining the ratio of NMR peak intensities in the presence and in the absence of plasma (I B /I F ). This relationship represents an easily measurable response of ligand binding that inversely depends on the fraction of bound ligand [9] . Spectra were obtained using an NMR experiment that includes a 40 ms T 2 filter, which enhances the effect on signal intensity caused by the interaction. A higher plasma concentration causes a decrease in the intensity of the NMR signals, consistently with a larger fraction of the drugs bound to plasmatic proteins. As Fig. 1 shows, the intensity decrease depends on the degree of binding: reported tighter binding ligands exhibit a larger broadening than weaker binding ligands for the same plasma dilution. This can be easily observed in the spectra outlined with a red box in Fig. 1 . Signal intensities decrease in the series Acetaminophen (
NMR signal intensity attenuation in the presence of plasma dilutions allows discriminating compounds accordingly to their PPB capacity
To explore if it is possible to discriminate quantitatively different PPB affinities using the decrease of signal intensity, we selected a set of compounds based on the previously reported f b in plasma. A total of twenty-five compounds, classified into four different categories related to their PPB capacities, were used to examine the ratio (I B /I F ) between the intensity of the NMR signals of compounds in the presence (I B ) and in the absence (I F ) of plasma in 1 H NMR experiments using different plasma concentrations (Fig. 2) .
Conditions were chosen in order to ensure that curves span a sufficiently wide range from 0.02 equivalents of HSA (dilution 1:1500) to one equivalent (dilution 1:30) with respect to the compound (20 M). As it is evident from the figure, the four groups show a differential behaviour, allowing a discrimination of the compounds based on their f b through the I B /I F ratio at any plasma dilution. For example, at the highest plasma concentration, low binders (f b < 0.5) present an I B /I F > 0.7, medium binders between 0.7 and 0.2, and high and very high binders an I B /I F < 0.2. On the other hand, at the lowest plasma concentration, high and very high binders are better discriminated.
Linear correlations are found between f b literature values and the attenuation of the NMR signal
Once ascertained the qualitative relationship between f b and I B /I F , we have investigated the possibility of using the intensity ratio to obtain a quantitative value for the degree of PPB. For this purpose, we selected two dilutions that allowed the best discrimination of the different f b values. Inspection of curves in Fig. 2 shows that measurements at a 1:400 dilution give a good separation of the I B /I F values within the range observed for very high and high binders, whereas at a 1:30 dilution the same condition is achieved for medium and weak binders.
Compounds in Tables 1 and 2 were selected to determine an empirical relationship between f b and I B /I F in the case of mediumlow and very high-high binders, respectively. To this end, we have measured the intensity ratio at the corresponding plasma dilution and plot the literature f b as a function of the I B /I F average of three replicates using three different plasma pools. This is important to cope also with the possible variation of plasma protein affinities in different plasma samples. Graphs in Fig. 3 show that there is a significantly strong correlation between I B /I F and f b for the two cases, with Pearson correlation coefficients of -0.9894 (P<10 −5 ) and -0.9592 (P<10 −5 ), for medium-low and very high-high binders, respectively. Data were fitted using linear equations, as the use Table 3 shows the compounds used for the fitting (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
of quadratics polynomials did not show a significant decrease in the variance between literature f b and calculated values (F-test, results not shown). Fig. 3 shows the corresponding empirical equations that allow the calculation of the f b value. Last columns of Tables 1 and 2 show the corresponding f b values determined using these equations. From these results, we can estimate an average uncertainty of 0.04 and 0.004 on the f b value of medium-low and very high-high binders, respectively.
Comparison of plasma protein binding determined by NMR with values obtained using RED and values reported in literature for a set of standard compounds
We have then measured the f b values of ten compounds, that were not previously used for the derivation of the linear equations shown above, using the NMR method and a well-established methodology, rapid equilibrium dialysis (RED) [10] . These f b values were then compared with literature values. As observed in Fig. 4 and Table 3 there is a very good agreement with the literature with only a few deviations. In particular, we have measured a lower f b value than that reported for Labetalol by RED, whereas measured Table 1 ) and strong binders (right panel, 1:400 plasma dilution, listed in Table 2 ). These equations are used for obtaining f b values from the experimental IB/IF value at the corresponding plasma dilution. (Fig. 3) . [20] 91.5 ± 0.6 a 1:400 plasma dilution was used for IB. Data are the average value of three replicates using different plasma samples. b Experimental plasma protein binding obtained from the best-fit line (Fig. 4) . f b values resulted higher for Labetalol by NMR and Bupropion by RED. Overall, the R 2 obtained for RED is very close to that originally presented by Singh et al. [10] , and not statistically different from that obtained by the NMR method (0.968 vs 0.981 for RED and NMR, respectively).
Medium through-put protocol for measuring plasma protein binding by NMR
The protocol of the NMR based method for measuring PPB is depicted in Fig. 5 . A first spectrum is obtained using a 20 M solution of the compound in PBS buffer, deuterated TSP for the measurement of the concentration, and formate as a control of field homogeneity. The control spectrum can be used to determine compound solubility and as quality check of the purity and structure of the molecule under study. The PPB for compounds showing a solubility significantly below 10 M cannot be measured by this method.
A second spectrum is obtained using a 1:30 plasma dilution, in the same conditions. Formate linewidth comparison between the first and second spectrum is crucial, because f b measurements rely on peak broadening occurring solely because of protein interaction, hence the need to work at constant field homogeneity. In this sense, TSP cannot be used because it interacts with plasmatic proteins, whereas formate does not [11] . If I B /I F is greater than 0.15, f b is directly obtained using the corresponding equation, and the compound is classified as a medium-weak binder. For I B /I F lower than 0.15, a third spectrum is acquired using a 1:400 dilution of plasma, from which f b is determined, and the compound is classified as a strong or very strong binder. Acquisition time for each NMR spectrum is 20 min using a 600 MHz spectrometer; therefore 40 min or one hour are required for recording the two or three NMR spectra and testing one compound, depending if it results a medium-weak or a strong-very strong binder. This makes it possible to test around 20 compounds per day using plasma from one species using a sample changer in order to acquire spectra under automation. The total price of this analysis is very low, as it includes only very little amount of plasma, buffer solutions and one NMR tube.
Differences in using plasma vs recombinant proteins
We have then compared the f b values obtained employing recombinant purified HSA and/or hAGP with those using diluted plasma. PPB of different compounds, including Urapidil, Verapamil, Ranitidine and two compounds that were synthesized for internal drug discovery programs (compounds Cpd-a and Cpd-b), were measured using four different conditions: a solution containing 1:30 dilution of plasma, two solutions containing the expected concentrations of HSA and hAGP at this plasma dilution (20 M and 1 M, respectively) and a solution containing both HSA and hAGP (Fig. 6) . Our results indicate that for compounds like Urapidil and Cpd-a that present a medium to high affinity for HSA, no significant differences exists in the values obtained for the mixture of the two proteins or plasma (Fig. 6A) . Interestingly, we have measured statistically different f b values for Ranitidine, Cpd-b and Verapamil when using plasma or purified proteins. For the first two compounds, our measurements indicate that they mainly interact with hAGP, resulting the apparent f b the same for hAGP alone or a mixture of HSA and hAGP (Fig. 6B) . On the other hand, PPB measured in plasma resulted significantly lower than those measured in the solution containing the two proteins. To exclude the possibility that the concentration of hAGP in the plasma pool used was lower than that expected, we repeated the PPB measurement for Ranitidine adding an extra concentration of 1 M recombinant hAGP to the plasma. The resulting f b for Ranitidine resulted higher than that observed for pure plasma (0.24 vs. 0.17, respectively), but still lower than that obtain for the solution containing only hAGP 1 M (0.37). This suggests that these compounds exhibit a reduced affinity for hAGP in plasma compared to that for the purified protein, probably due to the presence in plasma of competitors for the binding site. On the contrary, Verapamil, which binds with higher affinity to HSA than to hAGP, shows a higher f b when using plasma than in the case of the two purified proteins together (Fig. 6C ). This result can be explained considering that Verapamil interacts also with lipoproteins [12] , which is not taken into account when measuring PPB using only HSA and/or hAGP.
Increasing the throughput: Measuring pools of compounds
Finally, we have investigated the possible measurement of PPB using pools of compounds, with the purpose of increasing the throughput of the method. This can be important for screening a large number of compounds and efficiently detecting high binders of plasma proteins, using an f b value of 0.80 as a threshold. 
Discussion
In this work, we present a new method for assessing PPB of drug candidates using NMR spectroscopy based on the degree of line perturbation of the small molecule signals caused by interaction with plasmatic proteins. Differently from most of the known NMRbased methods to detect ligand-protein interaction, our method uses plasma and not purified proteins, and can provide a quantitative information about the bound fraction of the molecule using empirically derived linear relationships. The agreement with literature data is equivalent to that achievable with a well-established methodology like RED. As the main advantages of this method, it is worth mentioning that it involves a fast measurement with minimum of sample preparation and at a very low price per sample. In addition, the spectrum obtained for the isolated small molecule gives information about its solubility in buffer and serves as a quality check of the proposed structure. Finally, it is possible to assess the role of HSA and/or hAGP in the binding of the molecule. This information is particularly important in cases of binding to hAGP, because it can lead to dose-dependent behaviour of the pharmacokinetics (PK) parameters [4] , mainly due to saturation at high concentrations.
A significant number of methods were proposed to measure PPB [2] . All the methods currently in use present drawbacks: equilibrium dialysis has its limitations particularly for compounds with very high non-specific binding, plasma instability, or inability to diffuse through the dialysis membrane. Ultracentrifugation may be an alternative method for these types of compounds, but presents a long experiment duration and can yield false high binding [2] . In the case of the NMR method presented here, we can foresee that problems will arise in the case of a slow exchange between free and bound compounds. This scenario was not very frequently observed for interactions with albumin, the most concentrated protein in plasma, except for tryptophan (our experiments, data not shown) and fluoro-tryptophan [13] . It can be more common for compounds interacting with alpha-glycoprotein, although no examples are known. If exchange between the free and HSA bound forms of the small molecule is slow, which normally occurs for compounds showing a high affinity for the target, values of f b calculated at 1:400 dilution will be very low, and, contradictory, spectra obtained using the 1:30 dilution will show the almost complete disappearance of the small molecule signals. This behaviour, when detected, can be used to hypothesize a slow off-rate for dissociation of plasma proteins. This is not a minor point, since kinetics of the binding is an essential information to establish the role that PPB will play on the efficacy of a drug candidate [1] .
A particularly important feature of any method used for PPB measurement is its ability to distinguish between high (f b values between 0.90 and 0.99) and very high binders (f b >0.99). This is because it is mostly very strong binding that might have an influence on the therapeutic effect of drugs, making recognition of these compounds essential. The empirical relationship obtained between f b and I B /I F using a 1:400 plasma dilution shown in Fig. 3 makes the identification of very high binders feasible. A difference of 0.01 in f b between two compounds will translate into a change of 0.10 in I B /I F , well within the accuracy of the measurement. The use of higher plasma dilutions can lead to larger differences in the signal intensity ratio, making it possible to differentiate more accurately candidates in drug discovery programs dealing with very high binders.
Another important point underlined by our results is the advantage of using plasma for assessing PPB instead of purified recombinant proteins. Although some approaches like ultrafiltration and equilibrium dialysis employ plasma, others like Biacore technology or chromatography and capillary electrophoresis are constrained to the use of recombinant proteins [2] . This limitation also holds for all NMR methods developed so far to study the interaction between proteins and small molecules [8] . Given the multiple actors and conditions that determine PPB capacity, we decided to use plasma, which showed to be particularly important for compounds interacting with hAGP or lipoproteins. Our results show that, in some cases, f b values measured using plasma for compounds interacting almost exclusively with hAGP are lower than those obtained using the purified protein. This effect can be explained if one assumes that other compounds in plasma can compete for hAGP binding site. It is known that basic compounds can efficiently bind hAGP [14] . A large collection of small and positively charged compounds present at relatively high concentration in plasma can act lowering the apparent affinity of the tested compound. On the other hand, if the ligand interacts with lipoprotein, the use of solely HSA or hAGP will give a lower apparent f b as compared to that measured using plasma, like in the case of Verapamil. Taken altogether, these observations strengthen the importance of developing methodologies that use plasma and not recombinant proteins.
PPB values of drug candidates are usually monitored during the drug discovery phase with the intent to prioritize compounds that show a low f b . This common practice is based on the assumption that reducing PPB leads to a higher fraction of the active drug available to perform its pharmacological action. However, optimization of PPB needs to be strongly related to a good understanding of PK and PD parameters, which is the only way to evaluate the effect of protein binding on drug efficacy [2] . In many cases, a drug can show adequate tissue levels required for its pharmacological action in spite of showing a high PPB. For this reason, and many others described in the excellent review by Bohnert & Gan [2] , it is not recommended the use of significant resources to perform detailed PPB evaluation during the early stages of drug discovery. Fast, costeffective and highly reproducible methods like the one we present in this manuscript are perfectly suited to evaluate the PPB of compounds in the lead identification/optimization stages.
Conclusions
This manuscript describes a new method for assessing PPB of drug candidate using NMR that involves a fast measurement (20 min for each spectrum) with minimum of sample preparation; is cheaper than other methods for PPB calculation; includes a quality check of the chemical structure and solubility of compound and is suitable for automation. Particularly important is the use of plasma and not purified proteins, which can give PPB values different from those observed in physiological conditions and opens the possibility to measure PPB in plasma of different species.
